// App-Quantinova.ai

TPS4597 : A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

Researchers

Presenter

  • Marit Ahrens

Principal Investigators

  • John B. A. G. Haanen

  • Ekaterini Boleti

  • Marine Gross Goupil

  • Marc-Oliver Grimm

  • Sylvie Negrier

  • Philippe Barthelemy

  • Gwenaelle Gravis

  • Philipp Ivanyi

  • Jens Bedke

  • Daniel Castellano

  • Andrej Panic

  • Begona Mellado

  • Pablo Maroto-Rey

  • Sylvie Rottey

  • Stefanie Zschaebitz

  • Dorothee Deckbar

  • Arndt Hartmann

  • Lothar Bergmann

Medical Centers

  • Medical Clinic II, University Hospital, Frankfurt, Germany

  • Gustave Roussy, Villejuif, France

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • CHU Bordeaux, Bordeaux, France

  • Department of Urology, Universitaetsklinikum Jena, Jena, Germany

  • Department of Thoracic Oncology, Centre Leon Berard, Lyon, France

  • Institut de Cancérologie Strasbourg Europe,Strasbourg, France, Strasbourg, France

  • CHU, Strasbourg, France

  • Biostatistic, Institut Paoli-Calmettes, Aix-Marseille Universite, Marseille, France

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Eberhard Karls University, Tubingen, Germany

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Clinic for Hematology, University Hospital Essen, Essen, Germany

  • Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  • Ghent University Hospital, Heymans Institute of Pharmacology, Ghent, Belgium

  • Heidelberg University Hospital, Heidelberg, Germany

  • University Hospital Frankfurt, Frankfurt, Germany

  • Institute of Clinical and Molecular Virology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany

Locations

  • Germany

  • France

  • Netherlands

  • United Kingdom

  • Spain

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • non-clear cell renal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Fixed Dose

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT03075423

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved